Clinical Cancer Research

Aims & Scope

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic.

The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment.

The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	10.2
2024	10.00

SJR (SCImago Journal Rank)

Year	Value
2024	4.800

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	392

Journal Rank

Year	Value
2024	309

Journal Citation Indicator

Year	Value
2024	17406

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  Citation: 3806

  Authors: Rebecca, Maureen, Kathleen I., Wedad M., Harriet K., Carol A., Lavina A., Ellen, Ping, Steven A.

• X-Tile

  Citation: 2971

  Authors: Robert L., Marisa, David L.

• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  Citation: 2659

  Authors: Jedd D., Axel, Steven, Jeffrey S., Omid, Celeste, Michele, Michael, Oliver, Geoffrey, Rachel, F. Stephen

• Therapeutic Nanoparticles for Drug Delivery in Cancer

  Citation: 2408

  Authors: Kwangjae, Xu, Shuming, Zhuo (Georgia), Dong M.

• Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

  Citation: 2108

  Authors: W. Jeffrey, Jeri, M. Craig, Madeline, Mark C., Chandra, Arjan G. J., Jonathan W., Leon W. M. M.

• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  Citation: 2011

  Authors: Torsten O., Forrest D., Kristin, Maggie, Gamze, Zhiyuan, Tina, Chad, Dave, Lynn, Lars A., Joseph, Allen M., C. Blake, Matt, Charles M.

• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i>-Mutant Lung Cancers

  Citation: 1989

  Authors: Helena A., Maria E., Natasha, Camelia S., Maureen F., William, Mark G., Vincent A., Marc, Gregory J.

• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  Citation: 1972

  Authors: Janis M., Alison, Julie R., Haiying, Xiaoyu, Jung H., Lieping, Drew M., Suzanne L., Robert A.

• Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

  Citation: 1891

  Authors: Robert E.

• Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

  Citation: 1803

  Authors: Johann S., Howard I., R. Bruce, Christopher, M. Craig, Henk, Gerald V., Leon W.W.M., Kenneth J., Derek

---